...U.S. in July 2020, a few months after obtaining territorial rights in a deal with PharmaMar S.A....

...than Veklury remdesivir. The team had identified Aplidin’s target, EEF1A2, during research to find drug repurposing candidates for COVID-19, and PharmaMar S.A....
...Stanniocalcin 1 Danielle Golovin Aplidin, plitidepsin Veklury, remdesivir (GS-5734) Icahn School of Medicine at Mount Sinai University of California San Francisco PharmaMar S.A. Gilead...

...By Paul Bonanos, Associate Editor PharmaMar will likely need to conduct a new study of Zepzelca...
...grant full approval.If it did not show a survival benefit, Iannone said he expected that PharmaMar S.A....
...the market.Jazz paid PharmaMar $200 million up front in December 2019 to gain Zepzelca’s U.S. rights.PharmaMar...

...Sept. 25. President and CEO Kenneth Berlin will serve as interim CFO of the immunotherapy company.PharmaMar...
...serve as the unit’s VP and global head. Jimeno was VP of clinical development at PharmaMar...

...cancer portfolio FDA granted accelerated approval to Zepzelca lurbinectedin from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and PharmaMar S.A....
...II BioCentury Staff teplizumab (MGA031, PRV-031) Ilaris, canakinumab (ACZ885) Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) avalglucosidase alfa, NeoGAA, Neo-GAA (GZ402666) Provention Jazz Pharmaceuticals Inc. PharmaMar S.A. Novartis Takeda...

...slated for completion by year end. PharmaMar seeks to repurpose multiple myeloma drug for COVID-19 PharmaMar S.A....
...infection by the alpha coronavirus HCoV-229E with nanomolar potency. While SARS-CoV-2 is a beta coronavirus, PharmaMar...
...1 α 2 Influenza A HA - Influenza A virus hemagglutinin BioCentury Staff Bill & Melinda Gates Foundation PharmaMar S.A. Stanford...

...treat a form of amyloidosis. FDA granted Priority Review to an NDA for lurbinectedin from PharmaMar S.A....
...accelerated approval of the Pol II inhibitor, whose PDUFA date is Aug. 16. In December, PharmaMar...
...Transthyretin VEGF - Vascular endothelial growth factor Paul Bonanos, Associate Editor Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) BCX7353 vadadustat (MT-6548, akb-6548) PharmaMar S.A. Jazz...

...pain. At least one company is still pursuing the target. The Sylentis S.A. subsidiary of PharmaMar S.A....

...Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership...
...cell lung cancer as it continues to expand its pipeline beyond its flagship narcolepsy programs. PharmaMar S.A....
...million in commercial milestones from Jazz Pharmaceuticals plc (NASDAQ:JAZZ), plus high-teen to 30% tiered royalties. PharmaMar...

...PharmaMar seeking accelerated approval of SCLC candidate PharmaMar S.A. (Madrid:PHM) climbed €0.46 (29%) to €2.06 after the...
...Bonanos, Associate Editor and Mary Romeo, Assistant Editor cefiderocol (S-649266) Hetlioz, tasimelteon (VEC-162) MRNA-1893 Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) Moderna Inc. PharmaMar S.A. Shionogi...